Chicago Capital LLC Has $1.86 Million Stake in Pfizer Inc. (NYSE:PFE)

Chicago Capital LLC lessened its holdings in Pfizer Inc. (NYSE:PFE) by 7.5% in the fourth quarter, HoldingsChannel reports. The fund owned 70,169 shares of the biopharmaceutical company’s stock after selling 5,726 shares during the period. Chicago Capital LLC’s holdings in Pfizer were worth $1,862,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in PFE. Means Investment CO. Inc. lifted its position in Pfizer by 2.6% during the fourth quarter. Means Investment CO. Inc. now owns 64,973 shares of the biopharmaceutical company’s stock worth $1,724,000 after purchasing an additional 1,661 shares during the period. Abner Herrman & Brock LLC increased its position in Pfizer by 7.3% during the 4th quarter. Abner Herrman & Brock LLC now owns 14,750 shares of the biopharmaceutical company’s stock worth $391,000 after purchasing an additional 1,000 shares in the last quarter. KPP Advisory Services LLC increased its holdings in Pfizer by 6.9% in the 4th quarter. KPP Advisory Services LLC now owns 9,232 shares of the biopharmaceutical company’s stock worth $245,000 after purchasing an additional 594 shares in the last quarter. Lynch Asset Management Inc. boosted its stake in shares of Pfizer by 1.3% during the fourth quarter. Lynch Asset Management Inc. now owns 45,500 shares of the biopharmaceutical company’s stock valued at $1,207,000 after purchasing an additional 600 shares in the last quarter. Finally, HHM Wealth Advisors LLC boosted its position in Pfizer by 51.7% during the 4th quarter. HHM Wealth Advisors LLC now owns 9,347 shares of the biopharmaceutical company’s stock worth $248,000 after buying an additional 3,184 shares during the period. 68.36% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. Sanford C. Bernstein assumed coverage on shares of Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target on the stock. Guggenheim cut their target price on Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Finally, UBS Group lowered their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Stock Performance

NYSE:PFE opened at $26.51 on Monday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market cap of $150.20 billion, a price-to-earnings ratio of 35.82, a PEG ratio of 0.66 and a beta of 0.64. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The business’s fifty day moving average is $26.27 and its 200 day moving average is $27.86.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.49%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is presently 232.44%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.